Gilenya

Known as: Gilenia 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Background Fingolimod (Gilenya) is a sphingosine 1-phosphate receptor modulator. Fingolimod was first granted a European license… (More)
Is this relevant?
2015
2015
We describe posterior reversible encephalopathy syndrome (PRES) in a woman with multiple sclerosis treated with Gilenya… (More)
  • figure 1
  • figure 2
Is this relevant?
2013
2013
We present the results of a one-year follow-up study of 11 patients treated with gilenya. The results of cardiomonitoring (ECG… (More)
Is this relevant?
2011
2011
The immunomodulator drug Gilenya (FTY720), marketed as the first oral sphingosine-1-phosphate receptor (S1P-R) modulator for… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2011
Review
2011
M ultiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system (CNS) that is the leading cause of… (More)
Is this relevant?
Review
2010
Review
2010
389 suppressive effects, it could find a niche as part of a combination therapy. “Daclizumab has been used with lots of other… (More)
  • table 1
Is this relevant?
Review
2010
Review
2010
389 suppressive effects, it could find a niche as part of a combination therapy. “Daclizumab has been used with lots of other… (More)
  • table 1
Is this relevant?
Review
2010
Review
2010
Promising news on several therapies for severe and unmet medical needs is anticipated in the second quarter of 2010. A us fDA… (More)
Is this relevant?